



Contact: Ralph Barry, Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: rbarry@aegisthera.com

Aegis Therapeutics to Present at the “5th Annual Intranasal, Inhaled, and Pulmonary Drug Development and Delivery Symposium” in October 2006

SAN DIEGO, CA July 24, 2006/BusinessWire/-- Aegis Therapeutics, a leader in intranasal drug delivery, will present an overview of recent developments in nasal and transmucosal delivery of peptide, protein, and non-protein macromolecular drugs at the 5th Annual Intranasal, Inhaled, and Pulmonary Drug Development and Delivery Symposium organized by Pharmaceutical Education Associates. In a presentation entitled: “Overcoming Macromolecule Delivery Challenges: A Case Study”, Dr. Edward T. Maggio, President and CEO of Aegis, will describe the application of Aegis’ Intravail™ non-invasive drug delivery technology, and Aegis’ ProTek™ protein stabilization technology to specific protein therapeutics. The presentation is scheduled for Wednesday, October 11, 2006 at the Hilton Washington DC/ Silver Spring, MD.

Information about the symposium may be obtained from the following website:
<http://www.pharmedassociates.com/drug.asp#p255>

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Our ProTek™ technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek™ technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.

For more information about Aegis, please visit the Aegis website at:
<http://www.aegisthera.com>.

###